Field trials in USA in 2014, 2015.
GRAS status for our first colicin products in 2015 (GRN593), 2017 (GRN676) and 2018 (GRN775), GRAS status for our thaumatin sweetener in 2018 (GRN738) and 2020 (GRN910 and GRN920).
GRAS status for Clostridium bacteriophage endolysins (GRN802) and bacteriocin preparations specific to Salmonella (GRN824) in 2019.
GMP certification of the facility in Halle, Germany (divested with ICON); successful Phase I trials in USA with NHL cancer vaccine; Phase I-II with ZMapp anti-Ebola therapy (based on our technology).
Clear regulatory path for products based on our proprietory manufacturing process.